STOCK TITAN

Fennec Pharmaceuticals (FENC) DEF 14A Filings

FENC NASDAQ

Here are the DEF 14A proxy statements from Fennec Pharmaceuticals Inc. (FENC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow FENC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FENC filings page.

Rhea-AI Summary

Fennec Pharmaceuticals Inc. is holding a virtual annual and special shareholder meeting on June 10, 2026 to vote on key governance and compensation items. Shareholders of record at 5:00 p.m. EDT on April 13, 2026, each holding one vote per common share, may participate online.

Shareholders will elect five directors, appoint Haskell & White LLP as auditors, and cast advisory votes on executive compensation and on how often that say‑on‑pay vote should occur, with the board recommending every year. As of April 13, 2026, there were 34,712,756 common shares outstanding.

Special business includes increasing the share reserve under Fennec’s 2020 Equity Incentive Plan to 10,000,000 common shares, which the circular states equals about 28.81% of shares outstanding, and approving a separate 2026 Equity Inducement Plan covering up to 600,000 shares, primarily for newly hired employees. The proxy also details executive and director pay, outstanding options, and severance and change‑of‑control provisions for senior management.